DBV Technologies (FRA:DBV) Short Interest


FRA:DBV DBV Technologies SA FRA:DBV
27 GF Score
Price €2.77
! 1 Warning Sign
View Full Analysis

What is DBV Technologies Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:DBV vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, DBV Technologies's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DBV Technologies Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DBV Technologies's Short Interest distribution charts can be found below:

* The bar in red indicates where DBV Technologies's Short Interest falls into.


FRA:DBV
27GF Score
DBV Technologies SA FRA:DBV
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DBV Technologies Business Description

Address 107 Avenue de la Republique, Batiment IRO, Chatillon, Paris, FRA, 92320
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
27GF Score

Get the complete analysis for FRA:DBV

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.77
Price